Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018
September 24 2018 - 8:00AM
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage
company discovering, developing and commercializing novel
antibiotics to treat serious bacterial infections, today announced
that eight presentations and posters highlighting results from its
antibiotics portfolio and pipeline will be presented at the
Infectious Diseases Society of America IDWeek™ 2018 meeting, being
held October 3 to 7, 2018 in San Francisco, CA.
Poster and oral presentations for Melinta’s commercial and
clinical-stage programs follow.
Baxdela® (delafloxacin):
- Poster #2378 (October 6, 2018 from 12:30-1:45pm PT) -
Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin
and Skin Structure Infections (ABSSSI) with Delafloxacin (DLX)
IV/oral therapy
- Poster #2373 (October 6, 2018 from 12:30-1:45pm PT) -
Evaluation of Delafloxacin Activity and Treatment Outcome for Phase
3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial
Anaerobic Isolates
- Poster #2377 (October 6, 2018 from 12:30-1:45pm PT) - Outcomes
in patients with history of cardiac or vascular disease (CV) during
treatment of acute bacterial skin and skin structure infection
(ABSSSI) with delafloxacin (DLX) vs vancomycin/aztreonam
(VAN/AZ)
Orbactiv® (oritavancin):
- Presentation #1719 (October 6, 2018 from 9:45-10:00am PT) -
Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS
Trial
- Poster #1928 (October 6, 2018 from 12:30-1:45pm PT) -
Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs
Between Patients Who Were Treated with Oritavancin (ORI) or
Vancomycin (VAN) for a Skin Infection in the Outpatient
Setting
Minocin® (minocycline for injection):
- Poster #1387 (October 5, 2018 from 12:30-1:45pm PT) - Phase I
study to evaluate the safety and pharmacokinetics (PK) of single
and multiple ascending doses (SAD/MAD) of intravenous (IV)
minocycline in healthy adult subjects
Other Presentations:
- Poster #1181 (October 5, 2018 from 12:30-1:45pm PT) - Use of
the Combination Antibiogram in the Era of MDR Gram Negative
Pathogens
- Poster #290 (October 4, 2018 from 12:30-1:45pm PT) - Safety and
effectiveness of oral sodium fusidate (fusidic acid) as chronic
antibiotic suppressive therapy in patients with staphylococcal bone
or joint infections.
About Melinta Therapeutics Melinta
Therapeutics, Inc. is the largest pure-play antibiotics company,
dedicated to saving lives threatened by the global public health
crisis of bacterial infections through the development and
commercialization of novel antibiotics that provide new therapeutic
solutions. Its four marketed products include Baxdela®
(delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv®
(oritavancin), and Minocin® (minocycline) for Injection. It also
has an extensive pipeline of preclinical and clinical-stage
products representing many important classes of antibiotics, each
targeted at a different segment of the anti-infective market.
Together, this portfolio provides Melinta with the unique ability
to provide providers and patients with a range of solutions that
can meet the tremendous need for novel antibiotics treating serious
infections. Visit www.melinta.com for more information.
Cautionary Note Regarding Forward-Looking
Statements Certain statements in this communication
constitute “forward-looking statements” within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act and are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act and Section 21E of the Securities Exchange
Act and are making this statement for purposes of complying with
those safe harbor provisions. These forward-looking statements
reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control.
Risks and uncertainties for Melinta include, but are not limited
to: the fact that we have incurred significant operating losses
since inception and will incur continued losses for the foreseeable
future; our limited operating history; our need for future capital
and risks related to our ability to obtain additional capital to
fund future operations; uncertainties of cash flows and inability
to meet working capital needs as well as other milestone, royalty
and payment obligations; the fact that our independent registered
public accounting firm’s report on the Company’s 2016 and 2017
financial statements contains an explanatory paragraph that states
that the our recurring losses from operations and our need to
obtain additional capital raises substantial doubt about our
ability to continue as a going concern; our substantial
indebtedness; risks related to our commercial launches of our
products and our inexperience as a company in marketing drug
products; the degree of market acceptance of our products among
physicians, patients, health care payors and the medical community;
the pricing we are able to achieve for our products; failure to
obtain and sustain an adequate level of reimbursement for our
products by third-party payors; inaccuracies in our estimates of
the market for and commercialization potential of our products;
failure to maintain optimal inventory levels to meet commercial
demand for any of our products; risks that our competitors are able
to develop and market products that are preferred over our
products; our dependence upon third parties for the manufacture and
supply of our marketed products; failure to achieve the benefits of
our recently completed transactions with Cempra and The Medicines
Company; failure to establish and maintain development and
commercialization collaborations; uncertainty in the outcome or
timing of clinical trials and/or receipt of regulatory approvals
for our product candidates; undesirable side effects of our
products; failure of third parties to conduct clinical trials in
accordance with their contractual obligations; our ability to
identify, develop, acquire or in-license products; difficulties in
managing the growth of our company; the effects of recent
comprehensive tax reform; risks related to failure to comply with
extensive laws and regulations; product liability risks related to
our products; failure to retain key personnel; inability to obtain,
maintain and enforce patents and other intellectual property rights
or the unexpected costs associated with such enforcement or
litigation; risks relating to third party infringement of
intellectual property rights; our ability to maintain
effective internal control over financial reporting; unfavorable
outcomes in any of the class action and shareholder derivative
lawsuits currently pending against the Company; and the fact that a
substantial amount of shares of common stock may be sold into the
public markets by one or more of our large shareholders in the near
future. Many of these factors that will determine actual
results are beyond Melinta’s ability to control or predict.
Other risks and uncertainties are more fully described in our
Annual Report on Form 10-K for the year ended December 31, 2017,
and in other filings that Melinta makes and will make with the SEC.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. The statements made in this press release speak
only as of the date stated herein, and subsequent events and
developments may cause our expectations and beliefs to change.
While we may elect to update these forward-looking statements
publicly at some point in the future, we specifically disclaim any
obligation to do so, whether as a result of new information, future
events or otherwise, except as required by law. These
forward-looking statements should not be relied upon as
representing our views as of any date after the date stated
herein.
For More Information:
Media Inquiries:David Belian(203) 848-6276
Investor Inquiries:Lisa DeFrancesco(908) 617-1358
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Apr 2024 to May 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From May 2023 to May 2024